Encysive Avoids Additional Trials For Thelin NDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm has submitted a complete response to a recent FDA “approvable” letter using existing data for the pulmonary arterial hypertension drug.
You may also be interested in...
Encysive Dispute Resolution Request For Thelin Negged By FDA
Securing approval by conducting an additional Phase III study as requested by FDA would take years, CEO Cole tells “The Pink Sheet” DAILY.
Encysive Dispute Resolution Request For Thelin Negged By FDA
Securing approval by conducting an additional Phase III study as requested by FDA would take years, CEO Cole tells “The Pink Sheet” DAILY.
Encysive To Enter Dispute Resolution With FDA Over Third Thelin “Approvable” Letter
Company asserts that FDA’s data analysis of STRIDE-2 trial for Thelin does not follow special protocol assessment agreement.